Cargando…

Does the type of first-line regimens influence the receipt of second-line chemotherapy treatment? An analysis of 3211 metastatic colon cancer patients

With new agents entering the market, the sequencing of first-line (Tx1), second-line (Tx2), and subsequent chemotherapy/biologics regimens are being examined. We examined how Tx1 regimens impacted the likelihood of receiving Tx2 among metastatic colon cancer (mCC) patients. Surveillance, Epidemiolog...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zheng, Zhiyuan, Hanna, Nader, Onukwugha, Eberechukwu, Reese, Emily S, Seal, Brian, Mullins, C Daniel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Ltd 2014
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3930397/ https://www.ncbi.nlm.nih.gov/pubmed/24403130 http://dx.doi.org/10.1002/cam4.176

Ejemplares similares

Cost-Effectiveness of Second-Line Chemotherapy/Biologics among Elderly Metastatic Colon Cancer Patients
por: Zheng, Zhiyuan, et al.
Publicado: (2014)

Clinical and demographic characteristics associated with the receipt of chemotherapy treatment among 7951 elderly metastatic colon cancer patients
por: Reese, Emily S, et al.
Publicado: (2013)

Sequential Therapies and the Cost-Effectiveness of Treating Metastatic Colon Cancer Patients
por: Woldemichael, Andinet, et al.
Publicado: (2016)

Concordance between administrative claims and registry data for identifying metastasis to the bone: an exploratory analysis in prostate cancer
por: Onukwugha, Eberechukwu, et al.
Publicado: (2014)

Utilization of novel systemic therapies for multiple myeloma: A retrospective study of front‐line regimens using the SEER‐Medicare data
por: Goto, Daisuke, et al.
Publicado: (2019)

3211 Place, Poverty, and Prevention: A Mixed Methods Study
por: Kurani, Shaheen, et al.
Publicado: (2019)

Irinotecan plus fluorouracil‐based regimen as second or third‐line chemotherapy for recurrent or metastatic esophageal squamous cell carcinoma
por: Wang, Xi, et al.
Publicado: (2015)

Big Data and Its Role in Health Economics and Outcomes Research: A Collection of Perspectives on Data Sources, Measurement, and Analysis
por: Onukwugha, Eberechukwu
Publicado: (2016)

Valuing diversity in value assessment: introducing the PhRMA Foundation Health Disparities Challenge Award
por: Onukwugha, Eberechukwu
Publicado: (2021)

Prevalence and risk of skeletal complications and use of radiation therapy in elderly women diagnosed with metastatic breast cancer
por: Hussain, Arif, et al.
Publicado: (2018)

Factors associated with receipt of second-line recurrent or metastatic cervical cancer treatment in the United States: A retrospective administrative claims analysis
por: Sonawane, Kalyani, et al.
Publicado: (2022)

Factors associated with receipt of second-line recurrent or metastatic cervical cancer treatment in the United States: A retrospective administrative claims analysis
por: Sonawane, Kalyani, et al.
Publicado: (2022)

Second-line chemotherapy for the treatment of metastatic pancreatic cancer after first-line gemcitabine-based chemotherapy: a network meta-analysis
por: Citterio, Chiara, et al.
Publicado: (2018)

Second-line chemotherapy after early disease progression during first-line chemotherapy containing bevacizumab for patients with metastatic colorectal cancer
por: Yamamoto, Shun, et al.
Publicado: (2021)

First-line chemotherapy regimens for locally advanced and metastatic pancreatic adenocarcinoma: a Bayesian analysis
por: Zhang, Shuisheng, et al.
Publicado: (2018)

Effect of FOLFIRINOX as second-line chemotherapy for metastatic pancreatic cancer after gemcitabine-based chemotherapy failure
por: Kobayashi, Noritoshi, et al.
Publicado: (2017)

Dilemma of first line regimens in metastatic pancreatic adenocarcinoma
por: Ghosn, Marwan, et al.
Publicado: (2016)

Why the Gap in Evaluating the Social Constructs and the Value of Medicines?
por: McRae, Jacquelyn, et al.
Publicado: (2021)

Risk of skeletal related events among elderly prostate cancer patients by site of metastasis at diagnosis
por: Hussain, Arif, et al.
Publicado: (2016)

Erratum to Ponassi R, et al. Cell Cycle Volume 7, Issue 20; pp. 3211-24
por: Ponassi, Raffaella, et al.
Publicado: (2012)

Regional Chemotherapy Is a Valuable Second-Line Approach in Metastatic Esophageal Cancer after Failure to First-Line Palliative Treatment
por: Vashist, Yogesh, et al.
Publicado: (2022)

Skeletal-related events and mortality among men diagnosed with advanced prostate cancer: The impact of alternative measures of radiation to the bone
por: Onukwugha, Eberechukwu, et al.
Publicado: (2017)

Burden of Co-Infection: A Cost Analysis of Human Immunodeficiency Virus in a Commercially Insured Hepatitis C Virus Population
por: Mattingly, T. Joseph, et al.
Publicado: (2019)

FOLFOX as second-line chemotherapy in patients with pretreated metastatic pancreatic cancer from the FIRGEM study
por: Zaanan, Aziz, et al.
Publicado: (2014)

Evaluation of vinorelbine-based chemotherapy as the second or further-line treatment in patients with metastatic breast cancer
por: Cybulska-Stopa, Bożena, et al.
Publicado: (2013)

The prognostic value of D-dimer levels in metastatic osteosarcoma patients treated with second-line chemotherapy
por: Huang, Yujing, et al.
Publicado: (2016)

Exceptional Response to Second-Line Gemcitabine/Nab-Paclitaxel Chemotherapy in Patients With Metastatic Pancreatic Adenocarcinoma
por: Bukhari, Nedal, et al.
Publicado: (2021)

Study of Gemcitabine Plus Nab-Paclitaxel-Based Chemotherapy Regimen as First-Line Treatment in Metastatic Pancreatic Carcinoma
por: Domadia, Kshitij, et al.
Publicado: (2021)

Comparison of Two Chemotherapy Regimens After First-Line Treatment for HER2-Negative Metastatic Gastric Cancer
por: Urakçı, Zuhat, et al.
Publicado: (2023)

Kidney and Cancer Outcomes with Standard Versus Alternative Chemotherapy Regimens for First-Line Treatment of Metastatic Urothelial Carcinoma
por: Côté, Gabrielle, et al.
Publicado: (2023)

Value in Hepatitis C Virus Treatment: A Patient-Centered Cost-Effectiveness Analysis
por: Mattingly, T. Joseph, et al.
Publicado: (2019)

Gemcitabine and docetaxel as second-line chemotherapy in elderly patients with metastatic urothelial carcinoma: a retrospective analysis
por: Naiki, Taku, et al.
Publicado: (2018)

First Line and Second Line Chemotherapy in Advanced Cholangiocarcinoma and Impact of Dose Reduction of Chemotherapy: A Retrospective Analysis
por: Möhring, Christian, et al.
Publicado: (2021)

Insulin for type 2 diabetes: choosing a second-line insulin regimen
por: Barnett, A, et al.
Publicado: (2008)

The Economic Burden of Comorbid Obstructive Sleep Apnea Among Patients with Chronic Obstructive Pulmonary Disease
por: Hong, Yoon Duk, et al.
Publicado: (2020)

Optimal first-line and second-line treatments for metastatic renal cell carcinoma: current evidence
por: Sun, Maxine, et al.
Publicado: (2014)

From antiretroviral therapy access to provision of third line regimens: evidence of HIV Drug resistance mutations to first and second line regimens among Ugandan adults
por: Namakoola, Ivan, et al.
Publicado: (2016)

Multicenter phase II study of apatinib treatment for metastatic gastric cancer after failure of second-line chemotherapy
por: Ruan, Hanguang, et al.
Publicado: (2017)

Complete Radiologic Response of Metastatic Pancreatic Ductal Adenocarcinoma to Microwave Ablation Combined with Second-Line Palliative Chemotherapy
por: Blomstrand, Hakon, et al.
Publicado: (2020)

A phase II trial of cabazitaxel as second line chemotherapy in relapsed locally advanced and/or metastatic carcinoma of the penis
por: Challapalli, Amarnath, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_qvoijfhbjh598c2o2vqmmfeunu